Nearly all employers in the Business Group on Health's survey said they covered GLP-1 drugs for diabetes at 96%. More than two-thirds covered the drugs for obesity, while 34% covered them for cardiovascular conditions. Fewer than one-third said they covered the drugs for other conditions.